KALA BIO
KALA
15 hedge funds and large institutions have $1.21M invested in KALA BIO in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 17 closing their positions.
1,498% more capital inflows, than outflows
Capital inflows: $3.36M | Capital outflows: $210K
700% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 1
3.77% more ownership
Funds ownership: 0% → 3.77% (+3.8%)
46% less funds holding
Funds holding: 28 → 15 (-13)
76% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$1.06M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$679K |
| 3 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
+$489K |
| 4 |
State Street
Boston,
Massachusetts
|
+$427K |
| 5 |
BlackRock
New York
|
+$346K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$72.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$48.8K |
| 3 |
Virtu Financial
New York
|
-$26K |
| 4 |
ADAR1 Capital Management
Austin,
Texas
|
-$24.5K |
| 5 |
GSA Capital Partners
London,
United Kingdom
|
-$15K |
KALA Hedge Fund Activity: Q2 2026 in Review
15 of the 8,360 institutional investors tracked by Wall St. Rank reported a position in KALA BIO (KALA) for Q2 2026, worth a combined $1.21M — up 313% from $294K a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of KALA and 4 opened new positions — a net loss of 13 holders — while 1 trimmed existing stakes and 8 added.
The largest buyer was Vanguard Capital Management, adding an estimated $1.06M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $72.3K sold.
- 15 institutional investors held KALA BIO (KALA) as of Q2 2026, down from 28 in Q1 2026.
- Funds reported $1.21M of KALA BIO stock for Q2 2026, up 313% quarter-over-quarter.
- 4 funds opened new KALA BIO positions in Q2 2026 and 17 closed out, a net change of -13 holders.
- The largest KALA BIO buyer in Q2 2026 was Vanguard Capital Management, an estimated $1.06M added.
- The largest KALA BIO seller in Q2 2026 was Renaissance Technologies, an estimated $72.3K sold.
Based on aggregated 13F filings for Q2 2026.